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Human papillomaviruses (HPV) are the causative agents of cervical cancer and have been 
shown to increase expression of pro-angiogenic factors from infected cells.  Angiogenesis 
is linked to tissue hypoxia through the stabilization and activity of hypoxia inducible 
factor 1α (HIF-1α).  We investigated whether HPV31 proteins affect the levels of HIF-1α 
under normal and hypoxic conditions.  Our studies indicate that cells containing complete 
HPV31 genomes showed enhanced levels of HIF-1α upon treatment with the hypoxia 
mimic DFO but not in the absence of treatment.  This enhancement was due to protein 
stabilization and resulted in increased expression of some but not all HIF-1α downstream 
target genes.  Our studies further indicate that both HPV E6 and E7 were able 
independently to enhance induction of HIF-1α upon DFO treatment, suggesting that a 
mechanism other than reduced p53 levels is involved in HIF-1α protein stabilization.  
Enhancement of HIF-1α stability was not restricted to high risk HPV types, as HPV11, a 
low risk HPV type, also mediated a similar effect.  These findings shed light on the 
mechanisms by which HPV contributes to the angiogenesis both in benign cervical 
lesions as well as in cervical cancers. 
 
Introduction 
Human papillomaviruses (HPVs) are small, non-enveloped DNA viruses that persistently 
infect the keratinocytes of stratified squamous epithelia (zur Hausen, 1999).  HPVs are 
linked to a variety of malignancies including over 99% of cervical cancers (zur Hausen, 
1996).  HPVs infect the basal keratinocytes of stratified squamous epithelia (Longworth 
and Laimins, 2004).  As keratinocytes detach from the basement membrane and begin the 
process of squamous differentiation, HPV maintains the continued expression of cellular 
DNA replication proteins for use in replicating its own genome, and harnesses cellular 
regulatory mechanisms to control productive viral replication and expression of its capsid 
genes (Longworth and Laimins, 2004).   
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HPV gene products can induce many of the cellular changes characteristic of the 
tumor phenotype (Hanahan and Weinberg, 2000; Zitvogel, Tesniere, and Kroemer, 2006), 
including independence from growth control signals (Suprynowicz et al., 2000; 
Woodworth et al., 1992); bypass of growth inhibitory signals, especially cellular 
differentiation (Hudson et al., 1990; Ruesch and Laimins, 1998); resistance to apoptosis 
(Webster et al., 2000; Zhang, Spandau, and Roman, 2002); immune evasion (O'Brien and 
Saveria Campo, 2002); and angiogenesis (Toussaint-Smith, Donner, and Roman, 2004).  
The two primary viral oncogenes, E6 and E7, are the only HPV gene products that are 
consistently retained and expressed in cervical cancers, indicating these two factors are 
responsible for malignant progression induced by HPV infection (Munger et al., 2004).  
E6 and E7 function in large part by binding and promoting the degradation of cellular 
tumor suppressors p53 and pRb, respectively (Munger et al., 2004).  Degradation of pRb 
by E7 results in the activation of E2F transcription factors that drive expression of 
cellular genes responsible for the S phase of the cell cycle.  E7-driven cell cycle 
progression can result in or potentiate cell death by apoptosis through upregulation of p53.  
Degradation of p53 mediated by E6 blocks apoptosis to allow continued proliferation.  In 
addition to these well known activities, both oncogenes have a range of other targets 
(Munger et al., 2004), and the extent to which these additional interactions contribute to 
HPV associated carcinogenesis is not fully understood.   
One important characteristic of tumor development is the promotion of 
angiogenesis, or the formation of new blood vessels, which allows for access to nutrients 
and oxygen for growth (Hanahan and Folkman, 1996).  Angiogenesis is induced in 
response to hypoxia, or reduced tissue oxygen levels (Brat, Kaur, and Van Meir, 2003).  
Under hypoxic conditions, cells secrete a variety of cytokines and growth factors that 
induce proliferation, migration, and blood vessel formation by endothelial cells (Brat, 
Kaur, and Van Meir, 2003).  The cellular response to hypoxia is primarily regulated 
through the activity of the transcription factor hypoxia inducible factor-1 (HIF-1)(Bardos 
and Ashcroft, 2005; Brat, Kaur, and Van Meir, 2003).  HIF-1 has two subunits, of which 
HIF-1α is regulated by oxygen.  Under normal oxygen conditions (normoxia), the HIF-1α 
subunit is hydroxylated, targeting it for rapid degradation through the von Hippel-Lindau 
(VHL)/proteasome pathway.  In hypoxia, reduced oxygen levels block VHL-mediated 
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degradation, resulting in the accumulation of HIF-1α protein, which translocates to the 
nucleus and activates expression of HIF-1 target genes (Bardos and Ashcroft, 2005).  In 
addition to this hypoxia-dependent stabilization system, a range of other posttranslational 
modifications and signaling pathways, such as the PI3K/mTOR pathway, also affect HIF-
1α synthesis, stability, and activity (Abraham, 2004; Bardos and Ashcroft, 2005; Brat, 
Kaur, and Van Meir, 2003).   
In many cancers, angiogenesis occurs only late in tumor progression, but 
increased vascular density and production of angiogenic factors is a very early event in 
the development of HPV-induced pre-malignant lesions and cervical cancers (Smith-
McCune et al., 1997; Smith-McCune and Weidner, 1994).  Furthermore, several studies 
have reported that HPV gene products can influence the production of angiogenic factors 
(Chen et al., 2007; Clere et al., 2007; Tang et al., 2007; Toussaint-Smith, Donner, and 
Roman, 2004).  Despite these observations, the molecular mechanisms by which HPV 
proteins induce an angiogenic phenotype remain largely unexplored.  Since HIF-1α is a 
central mediator of the angiogenic response in hypoxia, we investigated whether HPV 
affects the levels of HIF-1α expressed under normoxic or hypoxic conditions.  Our 
results indicate that the levels of HIF-1α protein are increased in hypoxia when HPV 
oncogenes are present, and this was true for both high and low risk virus types.  
Furthermore, this increased HIF-1α induction resulted in increases in some but not all 
downstream effectors of the hypoxic response, suggesting that HPV specifically 
manipulates aspects of the cellular hypoxic response.     
 
Materials and Methods 
Cell Culture and creation of cell lines.  Keratinocyte-derived cell lines were cultured in 
E-medium containing mouse epidermal growth factor (5 ng/ml; BD Biosciences) with 
mitomycin C (Medac)-treated NIH 3T3 J2 fibroblast feeders as described previously 
(Meyers and Laimins, 1994).  Prior to harvesting keratinocytes for analysis, feeders were 
removed via treatment with versene.  To create cell lines containing HPV31 episomes, 
cloned viral DNA was freed from its plasmid vector by digestion with HindIII, 
unimolecularly ligated with T4 DNA ligase (New England Biolabs) overnight at 16ºC, 
and precipitated with isopropyl alcohol.  Human foreskin keratinocytes (HFKs) were 
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transfected with HPV genomes, selected with G418, and pooled cell populations were 
expanded and analyzed for episomal maintenance as described previously (Wilson and 
Laimins, 2005).  Creation of retroviral constructs has been described previously (Halbert, 
Demers, and Galloway, 1991; Moody et al., 2007).  Hypoxia was mimicked by treatment 
with 100 μM deferoxamine mesylate (DFO, Sigma).  Cycloheximide and rapamycin were 
obtained from Sigma.   
 
Western blot analysis.  Whole cell extracts were prepared using 1x lysis buffer (Cell 
Signaling) and concentrations were determined using the Bio-Rad (Bradford) protein 
assay.  SDS-PAGE and Western blotting were performed as described previously using 
50-100 micrograms of protein (Hebner et al., 2006).  HIF-1α antbody (BD Biosciences) 
was used at 1:500, and GAPDH (Abcam) 1:20,000.  Densitometry was performed using 
Scion Image for Windows (Scion Corp.)  
 
RNA analyses.  Total RNA was isolated using RNA STAT-60 (Tel-Test) according to 
the manufacturer’s directions, and Northern analysis was performed on total RNAs as 
previously described (Wilson, Fehrmann, and Laimins, 2005).  Total RNAs were reverse 
transcribed using the Omniscript RT kit (Qiagen) and subject to real time PCR analysis 
using primers specific for human VEGF (5’-TCTACCTCCACCATGCCAAGT-3’, and 
5’-GATGATTCTGCCCTCCTCCTT-3’), SYBR green PCR master mix (Applied 
Biosystems), and an ABI 7900 HT sequence detection system following the 
manufacturer’s directions.  Ribonuclease protection assays were performed using the 
RPA III kit from Ambion as described previously (Bodily and Meyers, 2005).  The probe 
for Interleukin-8 (IL8) was cloned by PCR into the KpnI/HindIII sites of pGEM 7Zf(+) 
using Vent polymerase (New England Biolabs) using primers 5’-
GCCGGTACCATGACTTCCAAGCTGGCCG-3’ and 5’-
GCCAAGCTTCTTTGATAAATTTGGGGTGG-3’.  The template (BCMGS neo IL8) 
was a gift from Steven Polyak at the University of Washington, Seattle, WA and was 
originally constructed by Naofumi Mukaida, Kanazawa University, Kanazawa, Japan.  
The internal control for cyclophilin was purchased from Ambion.  The CAIX and 
GLUT1 cDNAs were cloned into pcDNA 3.1(-) by RT-PCR using primers 5’-
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CGCCTCGAGGCATGGCTCCCCTGTGCCCC-3’ and 5’-
CGCGGTACCTCCAGCCTCTAGGCTCCAGT-3’ for CAIX, and 5’-CGCCTCGAG 
CTGCCATGGAGCCCAGCAGC-3’ and 5’-
CGCGGTACCGGCGACTCACACTTGGGAAT-3’ for GLUT1.  A cDNA encoding 
HIF-1α cloned into pcDNA was a gift of Eric Huang (NIH).  Northern probe templates 
were generated from pcDNA-derived plasmids by PCR using the T7 and SP6 primers, 
and Northern analysis was performed using 10-15 micrograms total RNA as described 
previously (Fehrmann, Klumpp, and Laimins, 2003).   
 
Luciferase assays.  A luciferase reporter consisting of a trimerized 24-mer containing 18 
base pairs from the hypoxia response element (HRE) of the phosphoglycerate kinase 
promoter, HRE-TK-Luc, was a gift from Navdeep Chandel, Department of Medicine, 
Northwestern University, Chicago, IL.  Cells were plated in a six-well dish the day prior 
to transfection and cotransfected with 1 microgram of a luciferase reporter and 50 
nanograms of the Renilla control vector pRL-TK (Promega) using FuGene (Roche 
Diagnostics) according to manufacturer’s instructions.  After overnight incubation, cells 
were treated with or without DFO for 8 hrs and then harvested for luciferase assay using 
the Dual Luciferase kit (Promega) according to manufacturer’s instructions.  Transfection 
efficiencies were normalized for Renilla luciferase activity.  HIF-1 dependent activity 
was calculated as the ratio of the activity in cells treated with DFO to that without DFO.   
 
Results 
HPV31 and 16 proteins enhance activation of HIF-1α under hypoxic conditions.  To 
determine whether expression of HPV genes had any influence upon HIF-1α  activation 
or levels in normoxia and hypoxia, we first examined whether HIF-1α levels were 
induced in hypoxia using an HPV31-containing cell line (CIN 612) derived from a 
premalignant cervical biopsy (Rader et al., 1990).  To facilitate analysis we used the 
hypoxic mimic drug, deferoxamine mesylate (DFO) which has been previously reported 
to increase the levels of HIF-1α in a manner similar to that seen following growth in 
1.5% oxygen (An et al., 1998).  As a control we examined the levels of induction with 
cobalt chloride, a second hypoxic mimic drug.  As seen in Figure 1a, treatment of CIN 
 5
612 cells with DFO or cobalt chloride induced similar levels of HIF-1α  protein as seen 
following growth for 12 hours in 1.5% oxygen.  For ease of use we used DFO treatment 
in subsequent experiments.  
We next investigated whether HPV proteins enhanced the levels of HIF-1α in 
normoxia or hypoxia.  Additional HPV31 positive cell lines were generated by 
transfection of HPV31 DNA into human foreskin keratinocytes (HFK) followed by drug 
selection and expansion (Wilson and Laimins, 2005).  This allowed us to make direct 
comparisons between normal keratinocytes and keratinocytes containing HPV genomes 
in the same genetic background.  Southern blotting confirmed that these cell lines 
maintained HPV episomes at similar copy number (not shown).  To ensure that any 
differences we observed were not a result of genetic factors, we performed all 
experiments multiple times using different HFK donors and compared HPV31-positive 
cells with HFKs from the same donor.  Cell lines were designated HK31 cells, and 
distinguished from each other according to the HFK donor (i.e. the HK31-1 line was 
derived from HFK-1, etc.)  HFKs and HK31 cells were treated with DFO for various 
lengths of time and compared the levels of HIF-1α by Western blot analysis.  As seen in 
Figure 1b, HIF-1α was not detected above background in either HFK cells or HK31 cells 
in the absence of DFO treatment.  This indicates that the presence of HPV genomes is not 
sufficient by itself to induce HIF-1α expression under conditions of normoxia.  Failure to 
detect HIF-1α in normoxia was also seen in cells containing only the HPV E6 and E7 
genes, and in cervical cancer cell lines HeLa and C33A (not shown).  After incubation 
with DFO, HIF-1α levels were increased in both cell types within 3 hours after the 
initiation of treatment.  This indicates HIF-1α levels can be increased in response to 
hypoxia in cells containing HPV.  However, HIF-1α levels were consistently increased to 
a higher degree in HK31 cells as compared to HFK cells, indicating that HPV31 proteins 
act to enhance induction of HIF-1α in hypoxia.  Quantitative analysis of eight 
experiments indicated that HIF-1α levels were approximately 2.5 fold higher on average 
in HPV31 positive cells as compared to HFK with a range of 1.5 to 7 fold (data not 
shown).  Similar enhancement of HIF-1α levels was also seen in cell lines harboring 
episomal forms of HPV16 (data not shown).  The multiple bands occasionally seen in 
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HIF-1α Western blots (see also Fig. 5) are of unknown significance, but have also been 
seen in other published reports (Schmid et al., 2004; Tang et al., 2007). 
The oncogenic herpesvirus, HHV8, increases the levels of HIF-1α in infected 
cells by increasing transcription of the HIF1A gene (Carroll et al., 2006), whereas 
regulation of HIF-1α usually occurs through post-translational mechanisms in other 
systems (Bardos and Ashcroft, 2005).  To determine if increased levels of HIF-1α seen in 
HK31 cells was due to increased transcription of the HIF1A gene, Northern blot analysis 
was performed on RNAs from DFO-treated HFKs and HK31 cells.  No differences in 
HIF-1α mRNA levels were found (Fig. 2a), indicating that the upregulation of HIF-1α is 
due to post-transcriptional events.  We next investigated whether the increase in HIF-1α 
protein levels was due to changes in protein stability.  HFKs or HK31 cells were treated 
with DFO for 6 hours, with the addition of cycloheximide for various lengths of time 
before harvesting.  Levels of HIF-1α were determined by Western blotting, and the half 
lives of HIF-1α  in both cell types were calculated, taking into account the difference in 
total expression levels between HFKs and HK31 cells.  Our studies found that the half 
life of HIF-1α was extended from approximately 39 minutes in HFKs to 59 minutes in 
HK31 cells (Fig. 2b).  These data indicate that enhanced induction of HIF-1α by HPV31 
is due to increased stability of the HIF-1α protein.   
The PI3K/mTOR pathway has also been reported to result in hypoxia-specific 
upregulation of HIF-1α protein synthesis, an effect that can be inhibited by treatment 
with rapamycin (Abraham, 2004; Bardos, Chau, and Ashcroft, 2004).  To investigate 
whether the mTOR pathway contributed to increased HIF-1α expression in HK31 cells, 
we treated cells with both DFO and rapamycin, and then examined HIF-1α levels by 
Western blot analysis.  Rapamycin had a minimal effect on induction of HIF-1α in either 
HK31 cells or HFKs, regardless of DFO treatment (Fig. 3).  We conclude that HPV 
proteins do not modulate HIF-1α protein levels through the PI3K/mTOR pathway under 
our culture conditions.   
 
Activation of HIF-1α target genes by HPV31.  HIF-1 regulates the transcription of 
dozens of genes associated with angiogenesis, tumorigenesis, and glycolytic metabolism, 
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many of which contain hypoxia response elements (HRE) in their promoters (Bardos and 
Ashcroft, 2005; Brat, Kaur, and Van Meir, 2003).  To investigate whether the ability of 
HIF-1 to act as a transactivator is altered in HK31 cells, we first used reporter plasmids 
containing several HREs located upstream of luciferase under the control of the tk 
promoter (Alam et al., 2004).  This HIF-1 responsive reporter was transfected into HK31 
cells or HFKs that had been infected as an LXSN drug resistance-encoding retrovirus as a 
control.  After overnight incubation, cells were treated with DFO for 8 hours or left 
untreated.  HIF-1 dependent luciferase activity in cell lysates is shown in Figure 4a as a 
ratio of luciferase activity in cells treated with DFO versus untreated cells.  While both 
HK31 cells and controls showed an increased level of HRE-dependent luciferase activity 
following treatment with DFO, HK31 cells showed a greater than two-fold increase in 
activity as compared to controls, in line with the enhanced HIF-1α levels we observed in 
HK31 cells.   
We next investigated whether expression of endogenous HIF-1 targets would be 
similarly enhanced in HPV-containing cells.  Vascular endothelial growth factor (VEGF) 
is an important pro-angiogenic HIF-1 target gene and a central player in angiogenic 
signaling (Rankin and Giaccia, 2008).  The levels of VEGF transcripts were examined by 
quantitative RT-PCR in normoxia and following treatment with DFO.  VEGF transcripts 
were induced to a higher level in HK31 cells than in HFKs following treatment with DFO, 
consistent with higher levels of HIF-1α in these cells (Fig. 4b).  We next sought to 
determine whether HPV would enhance the expression of all HIF-1 targets or only those 
associated with angiogenesis.  Among the many HIF-1 targets, carbonic anhydrase IX 
(CAIX), which helps control cellular pH, and GLUT1, a glucose transporter, are not 
associated directly with angiogenesis but are upregulated during carcinogenesis (Lee et 
al., 2007).  Northern blot analysis indicated CAIX transcripts were increased to a greater 
degree (mean of about 1.8 fold) in HK31 cells treated with DFO as compared to similarly 
treated HFKs.  In contrast, GLUT1 transcripts were expressed at similar basal levels in 
untreated HFK and HK31 cells, and induced to comparable levels following DFO 
treatment. 
HIF-1 regulates some genes which could be detrimental to the persistence of 
virally infected cells.  One of these is interleukin-8 (IL8), which, in addition to 
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angiogenic activity also promotes inflammatory responses (Brat, Kaur, and Van Meir, 
2003).  To test whether HPV31 induces IL8 in hypoxic conditions, we performed 
ribonuclease protection assays on RNA from cells treated or untreated with DFO.  As 
shown in Figure 4d, not only were transcripts for IL8 not induced by DFO in HFK-
derived cells, expression of this gene was dramatically reduced by HPV31, in contrast to 
the expression profile of HIF-1α protein (Fig. 1).  Together these experiments indicate 
that enhanced HIF-1α induction by HPV results in activation of a subset of HIF-1 target 
genes, and that HPV may alter the spectrum of genes activated by HIF-1α. 
 
Both E6 and E7 can enhance induction of HIF-1α.  HK31 cells maintain the entire 
HPV31 episomal genome, and so any of the HPV31 gene products could potentially be 
involved in regulating HIF-1α.  We investigated whether the oncogenes E6 and E7 were 
sufficient to enhance HIF-1α levels since these proteins are selectively retained in 
cancers and previous reports indicate that they are capable of regulating some angiogenic 
genes (Baker et al., 1987; Tang et al., 2007; Toussaint-Smith, Donner, and Roman, 2004).  
Furthermore, E6 promotes the degradation of p53 (Scheffner et al., 1990), which is 
reported to negatively regulate HIF-1α stability in hypoxia (Ravi et al., 2000).  HFKs 
stably expressing HPV31 E6 or E7 were generated following  infection with LXSN-based 
retroviral vectors, selection for G418 resistance, and expansion in culture (Thomas and 
Laimins, 1998).  Following treatment with DFO, the levels of HIF-1α were examined.  
As seen in Figure 5a and b, HPV31 E6 and E7 were each sufficient on their own to cause 
enhanced induction of HIF-1α upon DFO treatment.  Similar effects were seen in cell 
lines expressing E6 or E7 from HPV16 (Fig. 5c).  In none of these cell lines were the 
levels HIF-1α transcripts altered (Fig. 2a).  We confirmed that p53 levels were reduced in 
E6-expressing cells and enhanced in E7 expressing cells, in line with previous 
observations (Eichten et al., 2002; Scheffner et al., 1990) (data not shown).  This 
indicates that the mechanism(s) regulating enhanced stability of HIF-1α in HPV positive 
cells does not depend exclusively on p53 protein levels.   
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Low risk HPV11 also enhances HIF-1α levels upon DFO treatment.  Infection by 
low-risk HPV types induces benign hyperproliferations that rarely progress to cancers.  
Stabilization of HIF-1α as a mechanism of inducing angiogenesis during the 
development of cancers has been well documented (Zhou et al., 2006), but benign HPV-
induced lesions likely also require the expression of angiogenic factors to ensure 
adequate oxygen and nutrient supply for growth.  We therefore sought to determine 
whether cells containing the low risk type HPV11 would also show enhanced induction 
of HIF-1α under hypoxic conditions.  For these studies, we transfected HFKs with cloned 
and recircularized HPV11 genomes (Oh, Longworth, and Laimins, 2004).  Following 
drug selection and expansion, we determined by Southern analysis that viral DNA was 
maintained as episomes (not shown).  We then treated HPV11 positive cells with DFO 
and examined the levels of HIF-1α by Western blot analysis.  As shown in Figure 6, HIF-
1α expression in hypoxia was enhanced in HFKs containing HPV11 episomes, similar to 
the effect seen with HK31 cells.  Thus, the increased levels of HIF-1α proteins induced 
during hypoxia appears to be a property of both high and low risk papillomaviruses.   
 
Discussion 
 The development of cervical cancers requires angiogenesis, but exhibits some 
unique differences from other solid tumors.  Normal stratified epithelia, including cervix, 
have characteristics of chronically hypoxic tissue, such as HIF-1α stabilization and 
VEGF expression, which are further increased during progression to malignancy (Evans 
et al., 2006; Lee et al., 2007; Mayer et al., 2004; Mazibrada et al., 2008; Smith-McCune 
et al., 1997).  Increased vascularity is observed in low grade HPV infections of the cervix, 
while this is usually a late event in the progression of many other cancers (Mazibrada et 
al., 2008; Smith-McCune et al., 1997; Smith-McCune and Weidner, 1994).  From the 
early stages of infection to lesion development and eventually progression to cancer, 
HPV modulates the cellular response to hypoxia.  Our results indicate that HPV enhances 
the levels of HIF-1α through protein stabilization, resulting in the increased expression of 
a subset of HIF-1 target genes.  This enhanced expression likely plays a central role in the 
progression of HPV-induced disease.   
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Our studies provide insight into how HIF-1α levels are manipulated by HPV 
proteins.  We found that upregulation of HIF-1α by HPV proteins was not limited to 
cervical cancers, but was also induced early, precancerous cells that stably maintained 
HPV episomes.  Furthermore, both high-risk HPV16 and 31 as well as the low risk 
HPV11 were found to be equally capable of enhancing HIF-1α levels, indicating that 
manipulation of the hypoxic response is important for many papillomavirus types.  This 
may not be surprising, given that nutrient and oxygen delivery are required in 
proliferating lesions regardless of whether they are induced by high or low risk viruses.  
Our studies also indicate that the effects of HPV proteins on HIF-1α levels occur 
specifically in hypoxia and not normoxia.  Since cervical tissues have characteristics of 
chronic hypoxia even under normal conditions (Lee et al., 2007; Mayer et al., 2004; 
Smith-McCune et al., 1997), HPV-infected cervical cells in vivo may activate angiogenic 
factors before the development of high-grade cancers.  E6 and E7 were found to be 
independently capable of enhancing HIF-1α levels, resulting in selective activation of 
downstream target genes.  Previous studies have shown that p53 is a negative regulator of 
HIF-1α activation and that transient expression of E6 leads to increased levels of HIF-1α 
which was attributed to decreased levels of p53 (Ravi et al., 2000).  HPV16 E7 increases 
the stability of p53 but can interfere with some of its functions (Eichten et al., 2002; 
Jones et al., 1999).  E6 and E7 were found in our studies to be equally efficient at 
enhancing HIF-1α stabilization.  This indicates that activation of HIF-1α in HPV positive 
cells is not strictly dependent on p53 protein levels, but whether E6 and E7 alter HIF-1α 
through alteration of p53 function remains to be determined.    
A wide range of cellular factors and pathways have been reported to affect HIF-
1α protein levels (Bardos and Ashcroft, 2005; Brat, Kaur, and Van Meir, 2003).  A 
previous report (Huh et al., 2007) has shown that E7 can interact with a cullin2 ubiquitin 
ligase complex that has been reported to mediate VHL-dependent HIF-1α degradation 
(Brat, Kaur, and Van Meir, 2003).  Alteration of the activity of this complex by E7 
should affect the level of HIF-1α in normoxia.  However, we failed to detect HIF-1α in 
normoxia, even in cells expressing E7.  This suggests that the normal VHL-mediated 
HIF-1α degradation pathway still functions in HPV-infected cells regardless of any 
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effects E7 may have on other aspects the VHL pathway.  Furthermore, there was no 
strong effect of rapamycin on HIF-1α levels, either with or without treatment with DFO, 
suggesting that the mTOR pathway (Abraham, 2004) is also not a major player.  The loss 
of PML has been reported to result in hypoxia-specific enhancement of HIF-1α induction 
(Bernardi et al., 2006), and PML can be targeted by E7 (Bischof, Nacerddine, and Dejean, 
2005).  Loss of p53 has also been reported to enhance HIF-1α induction in hypoxia (Ravi 
et al., 2000).  Both E6 and E7 were independently sufficient to alter HIF-1α levels, and 
although E6 and E7 affect the absolute levels of p53 protein in opposite ways, both 
oncogenes have been reported to affect the function of p53 (Munger et al., 2004).  Thus 
we cannot rule out a possible effect on the p53 function as mechanism for HPV-induced 
enhancement of HIF-1α.  
Several studies have shown that high-risk E6 and E7 can activate expression or 
enhance levels of a number of angiogenic factors, but it was not established that HIF-1α 
activation was responsible (Toussaint-Smith, Donner, and Roman, 2004).  Transfection 
of siRNAs against HPV18 E6 was found to reduce VEGF expression in HeLa cells (Clere 
et al., 2007).  In addition, conditioned supernatants from HPV16 E6 or E7 expressing 
cells were able to induce tube formation and proliferation of endothelial cells consistent 
with the activation of angiogenic factors (Bequet-Romero and Lopez-Ocejo, 2000; Chen 
et al., 2007; Lopez-Ocejo et al., 2000; Tang et al., 2007).  Using transient transfections of 
cervical cancer cells, E6 and E7 were able to increase expression of genes associated with 
angiogenesis which are also responsive to HIF-1 (Clere et al., 2007; Lopez-Ocejo et al., 
2000; Tang et al., 2007).  Finally, transient transfection of E6 and E7 expression vectors 
into cervical cancer cell lines was reported to induce HIF-1α levels under normoxic 
conditions but without altering protein stability (Tang et al., 2007).  In contrast, our 
studies using stable cell lines show that HIF-1α can be upregulated by E6 and E7 but 
only in hypoxia and through protein stabilization.  We suggest that the hypoxia-specific 
stabilization effect that we report is more likely to reflect conditions in vivo, given that 
our cells stably express HPV proteins.   
The enhanced levels of HIF-1α in HPV positive cells were found to activate some 
downstream genes such as VEGF and CAIX.  On the other hand, upregulation of IL8 and 
GLUT1 were either not seen or not enhanced in HPV positive cells.  This indicates that 
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HPV proteins have a mechanism to modulate the spectra of HIF-1 target genes that are 
activated upon DFO treatment.  Studies from the Roman laboratory (Toussaint-Smith, 
Donner, and Roman, 2004) have shown that cells expressing HPV oncogenes can induce 
the expression of angiogenic genes such as VEGF even in non-hypoxic conditions.  The 
state of HIF-1α was, however, not examined and it is possible that there was low level 
activation in their cells that was not observed in our assays.  Alternatively, it is possible 
that HIF-1 independent mechanisms are responsible for activation of these genes.  Our 
studies examining the levels of VEGF in normoxia showed low levels of expression in 
HPV positive cells in the absence of DFO, consistent with HIF-1 independent 
mechanisms of activation.  It is also possible that different culture methods could be 
responsible for the effects observed.  Consistent with published studies, we have 
observed that HIF-1α can be induced in normoxia by growth at high confluency (data not 
shown, see also (Rempe et al., 2007)) which could lead to activation of angiogenic genes.  
Our survey of angiogenesis mediators produced in HPV positive cells was not as 
complete as Toussaint-Smith et al., but we note that there appears to have been a 
somewhat higher expression of VEGF in HK31 cells and in some experiments CAIX (not 
shown) in the absence of DFO treatment.  In any case, more detailed analysis of HIF-1 
downstream mediators will be needed to understand the role of hypoxia and HIF-1α 
stabilization in the angiogenic phenotype in HPV infection.  
Finally, it was possible that the replication or transcription of the HPV31 genomes 
was sensitive to hypoxia, but we found that there was no effect of 12 hours of DFO 
treatment on viral copy number, and only a slight increase in viral transcripts and 
luciferase activity from early and late promoter reporters (unpublished).  Whether viral 
replication and gene expression are impacted by more chronic hypoxia remains to be 
determined.  In summary, we have found that several HPV types cause a hypoxia-specific 
enhancement of HIF-1α expression, an effect mediated by increasing stability of the HIF-
1α protein.  Furthermore, this increased HIF-1α expression is reflected in increases in 
some but not all downstream effectors of the hypoxic response, and is seen upon the 
expression of either E6 or E7.  These results shed light on the relationship between HPV 
infection and hypoxia in the development of cervical cancer and may help us better 
understand how to manage HPV-induced disease. 
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Figure 1. Over-induction of HIF-1α in HPV31 containing cells.  a. CIN 612 cells were 
treated with the indicated compound for 12 hours or 1.5% oxygen for 48 hours.  Total 
cell extracts were examined for HIF-1α levels by Western blotting.  b. HFK-1 and HK31-
1 cells were treated with 100 μM DFO for the indicated times, and lysates were analyzed 
by Western blotting for HIF-1α expression.   
 
Figure 2. HIF-1α regulation by increased protein stability.  a. HFK-1 cells, HK31-1 
cells, or HFKs transduced with the indicated HPV16 oncogene(s) were treated with 100 
μM DFO for the indicated times.  Total RNA was isolated and subjected to Northern 
analysis using a probe specific for HIF-1α.  b. HFK cells or HK31 cells were treated with 
DFO for 6 hours.  Cycloheximide (50 μg/ml final) was added at the indicated times 
before cells were harvested.  Lysates were analyzed by SDS-PAGE/Western blot for 
HIF-1α.  Band densities from three independent experiments were normalized first to the 
level of GAPDH in each sample and then to the total level of HIF-1α without 
cycloheximide treatment for each cell line.  Bars represent ± one standard error of the 
mean.   
 
Figure 3. Effect of rapamycin on HIF-1α protein levels 
a. HFKs or HK31-2 cells were treated with the indicted drug for 6 hours.  Total cell 
lysates were analyzed for HIF-1α expression by Western blotting.  b. Band densities from 
three independent experiments were normalized first to the level of GAPDH in each 
sample and then to the total level of HIF-1α without treatment for each cell line.  Bars 
represent ± one standard error of the mean 
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 Figure 4.  Regulation of HIF-1 targets by HPV31.  a. HK31-1 or HFK-1 cells 
transduced with a LXSN retroviral vector were transfected with the HRE-TK-Luc 
reporter plasmid.  The next day, cells were treated or untreated with 100 μM DFO for 8 
hours and assayed for luciferase activity.  The data points represent a ratio of the activity 
with DFO treatment to the activity without for three experiments and bars represent ± one 
standard error of the mean.  b. Total RNAs from HK31-1 or HFK-1 cells treated with 
DFO for the indicated times were subjected to reverse transcription followed by real-time 
PCR using primers specific for VEGF.  Bars represent ± one standard error of the mean.  
Total RNAs from the HFK-3 or HK31-3 cells were examined for expression of (c) CAIX 
or GLUT1 by Northern analysis or (d) IL8 expression by ribonuclease protection assay.   
 
Figure 5. Enhanced induction of HIF-1α in cells expressing either E6 or E7 from 
HPV16 or 31.  HFKs or HFKs transduced with either HPV31 E7 (a) or HPV31 E6 (b) 
were treated with 100 μM DFO for the indicated times, and analyzed by Western blot for 
HIF-1α expression.  c. HFK cells or HFKs expressing the indicated HPV16 oncogenes 
were treated with 100 μM DFO for the indicated times and analyzed by Western blot for 
HIF-1α expression.   
 
Figure 6. Effect of HPV11 on HIF-1α induction. 
HFKs or HFKs containing HPV11 episomes were treated with 100 μM DFO for the 
indicated time and analyzed by Western blotting for the expression of HIF-1α.   
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